A Controlled Trial of Inhaled Bronchodilators in Familial Dysautonomia

Area of Science:

• Pulmonary Medicine
• Genetics
• Pharmacology

Background:

• Chronic lung disease is a primary cause of mortality in familial dysautonomia (FD).
• Obstructive airway disease is prevalent in FD, but its reversibility is unknown.
• This study focuses on patients with FD homozygous for the IKBKAP founder mutation.

Purpose of the Study:

• To determine if airway obstruction in familial dysautonomia (FD) is pharmacologically reversible.
• To compare the effectiveness and safety of albuterol and ipratropium bromide in FD patients.
• To assess the cardiovascular effects of these bronchodilators in FD.

Main Methods:

• A double-blind, placebo-controlled, randomized clinical trial was conducted.
• 14 patients received albuterol, ipratropium bromide, or placebo via nebulizer on separate days.
• Airway responsiveness was measured by spirometry and impulse oscillometry; cardiovascular effects were continuously monitored.

Main Results:

• Both albuterol and ipratropium bromide demonstrated significant bronchodilator effectiveness, improving FEV1.
• Impulse oscillometry indicated a reduction in total airway resistance after nebulization.
• Neither medication caused significant adverse cardiovascular effects, including heart rate, rhythm, or blood pressure changes.

Conclusions:

• Airway obstruction in a subset of familial dysautonomia patients is pharmacologically reversible.
• Albuterol and ipratropium bromide are safe and effective short-term treatments for bronchodilation in FD.
• These findings suggest potential therapeutic strategies for managing respiratory symptoms in FD.